NorthStar Medical Radioisotopes is striving to become a major player in the healthcare field of Nuclear Medicine. It has forged new relationships, developed new and novel technologies and introduced some of these technologies to solve emerging medical problems in the U.S. It has been selected as one of recipients of funding from the National Nuclear Security Administration to assist with domestic production of Molybdenum99. Our linear accelerator technology approach is by far the most advanced and provides for a highly reliable production solution that maximizes safety. It has a major advantage over other approaches that use Uranium since NorthStar's process uses naturally occurring Molybdenum which does not produce large amounts of hazardous waste by-products due to fission. NorthStar's production process can offer highly redundant and scalable production capability.

Our approach will immediately address the U.S. demand for this important isotope, while producing minimal waste that can easily be handled by existing methods. By using easily obtained raw materials, recycling those raw materials and providing a complete distribution solution, NorthStar intends to be a low cost leader. Its automated separation system, the TechneGen, will produce a highly pure and sterile Technetium drug product.

NorthStar is also developing another highly reliable production route with resources at Missouri University Research Reactor in Columbia Missouri. NorthStar has produced and will be able to provide significant marketable quantities of Molybdenum99 for the Nuclear Medicine marketplace in the very near future. NorthStar is in a position to become the leader in U.S. domestic production and will be enabling the future of Nuclear Medicine.